Bioactive prolactin levels and risk of breast cancer: A nested case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 73-80

  Tworoger, Shelley S ^a,b   Rice, Megan S ^a,b   Rosner, Bernard A ^a,b   Feeney, Yvonne B ^c   Clevenger, Charles V ^d   Hankinson, Susan E ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROLACTIN;

ADULT; ARTICLE; BIOASSAY; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOASSAY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MIDDLE AGED; PARITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; BREAST TUMOR; METABOLISM; PILOT STUDY; PROSPECTIVE STUDY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; PILOT PROJECTS; PROLACTIN; PROSPECTIVE STUDIES;

EID: 84921058800     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0896     Document Type: Article

References (54)

1. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003;14:599-607.
2. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013;73:4810-9.
3. Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjonneland A, et al. Circulating prolactin and breast cancer risk among pre-and postmenopausal women in the EPIC cohort. Ann Oncol 2014;25:1422-8.
4. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
5. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354-69.
6. Garcia M, Colombani-Vidal ME, Zylbersztein CC, Testi A, Marcos J, Arturi A, et al. Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus. Lupus 2004;13:575-83.
7. Haro LS, Lee DW, Singh RN, Bee G, Markoff E, Lewis UJ. Glycosylated human prolactin: alterations in glycosylation pattern modify affinity for lactogen receptor and values in prolactin radioimmunoassay. J Clin Endocrinol Metab 1990;71:379-83.
8. Hoffmann T, Penel C, Ronin C. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 1993; 16:807-16.
9. Bulatov AA, Osipova TA, Makarovskaia EE. Comparison of biological activity of high molecular weight and low molecular weight forms of immunoreactive prolactin from human serum in cultured lymphoma NB2 cells. Vopr Med Khim 1996;42:234-9.
10. Maddox PR, Jones DL, Mansel RE. Prolactin and total lactogenic hormone measured bymicrobioassay and immunoassay in breast cancer. Br J Cancer 1992;65:456-60.
11. Kuo CB, Wu W, Xu X, Yang L, Chen C, Coss D, et al. Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes beta-casein gene expression in the rat mammary gland. Cell Tissue Res 2002;309:429-37.
12. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003; 144:5300-7.
13. Wu W, Chen YH, Ueda E, Tan D, Bartolini P, Walker AM. Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol Res 2006; 16:75-84.
14. Lawson DM, Sensui N, Haisenleder DH, Gala RR. Rat lymphoma cell bioassay for prolactin: observations on its use and comparison with radioimmunoassay. Life Sci 1982;31:3063-70.
15. Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen HG. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980;51:1058-63.
16. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The NursesHealth Study II. Endocr Relat Cancer 2006;13:583-92.
17. Rose DP, Berke B, Cohen LA. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay. Horm Metab Res 1988; 20:49-53.
18. Rose DP, Berke B, Cohen LA, Lahti H. A comparison of serum and breast duct fluid-immunoassayable prolactin and growth hormone with bioassayable lactogenic hormones in healthy women and patients with cystic breast disease. Cancer 1987;60:2761-5.
19. Rose DP, Cohen LA, Berke B, Boyar AP. Effect of a low-fat diet on hormone levels in women with cystic breast disease. II. Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones. J Natl Cancer Inst 1987;78:627-31.
20. Love RR, Rose DP. Elevated bioactive prolactin inwomenat risk for familial breast cancer. Eur J Cancer Clin Oncol 1985;21:1553-4.
21. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
22. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4: 649-54.
23. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006;66:2476-82.
24. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972-8.
25. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 1995;146:695-705.
26. Gout PW, Beer CT, Noble RL. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 1980;40: 2433-6.
27. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 2008;167:653-66.
28. Stunkard AJ, Sorensen T, Schulsinger F. Use of the Danish Adoption Register for the study of obesity and thinness. In: The genetics of neurological and psychiatric disorders. edn. Edited byKety SS, Rowland LP, Sidman SW, Mathysee SW. New York City: Raven Press; 1983: 115-20.
29. Rosner BA. Fundamentals of Biostatistics, 6 edn. Belmont, CA. Duxbury Press; 2005.
30. Eliassen AH, Tworoger SS, Hankinson SE. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 2007;120:1536-41.
31. Leanos-Miranda A, Cardenas-Mondragon G, Rivera-Leanos R, Ulloa-Aguirre A, Goffin V. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. Clin Endocrinol (Oxf) 2006;65:146-53.
32. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000;26:540-7.
33. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-5.
34. Lachelin GC, Yen SC, Alksne JF. Hormonal changes following hypophysectomy in humans. Obstet Gynecol 1977;50:333-9.
35. Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal 2011;23:1794-805.
36. Jacobson EM, Hugo ER, Borcherding DC, Ben-Jonathan N. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov Med 2011;11:315-24.
37. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003;79:241-52.
38. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999;140:5447-50.
39. Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, von der Thusen JH, Twickler MT, et al. Functional consequences of prolactin signaling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med 2012;16:2035-48.
40. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 1999;96:1246-51.
41. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004;64:6814-9.
42. Willett WC. Nutritional Epidemiology, vol., 2nd edn. New York: Oxford University Press; 1998.
43. Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control 2013;24:741-8.
44. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Cancer Clin Oncol 1987;23: 1541-8.
45. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988;24:1225-31.
46. Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC. Elevated levels of prolactin in nulliparous women. Br J Cancer 1981;43:826-31.
47. Espinosa de los Monteros A, Cornejo J, Parra A. Differential prolactin response to oral metoclopramide in nulliparous versus parous women throughout the menstrual cycle. Fertil Steril 1991;55:885-9.
48. Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JR. Longterm effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987;316:229-34.
49. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, et al. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet 2007; 8:72.
50. Rose DP. Hormones and growth factors in nipple aspirates from normal women and benign breast disease patients. Cancer Detect Prev 1992;16: 43-51.
51. Kwa HG, Cleton F, Bulbrook RD, Wang DY, Hayward JL. Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth. Int J Cancer 1981;28:31-4.
52. Su X, Hankinson SE, Clevenger CV, Eliassen AH, Tworoger SS. Energy balance, early life body size, and plasma prolactin levels in postmenopausal women. Cancer Causes Control 2009;20:253-62.
53. Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 2007;14:721-32.
54. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007;9: 464-76.